Markets:

Overview

News

Currencies

International

Treasuries

(OP:LOBEF)

0.0544 -0.0006 (-1.09%)

Streaming Delayed Price Updated: 2:08 PM EDT, Sep 16, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about LOBEF

< Previous 1 2 3 Next >

Psychedelic-Derived Medicines for Neurologic Conditions Fueling Large Revenue Growth in Projected $4 Billion Dollar Industry

January 26, 2023

EQNX::TICKER_START (OTCQB:LOBEF),(NASDAQ:ATAI),(NASDAQ:CMPS),(NYSE:CYBN),(NASDAQ:MNMD) EQNX::TICKER_END

Via FinancialNewsMedia

Topics Economy

Lobe Sciences, Ltd. Enters Collaborative Clinical Research Agreement with Integrative Headache Medicine of New York to Study the Effects of L-130 in the Treatment of Chronic Cluster Headache

January 26, 2023

Dr. Lauren R. Natbony to be Principal investigator Vancouver, BC – January 26, 2023 — Lobe Sciences Ltd. (OTCQB: LOBEF) (CSE: LOBE) (“Lobe” or the “Company”), a North American Biopharmaceutical company...

Via FinancialNewsMedia

Mass-Scale Psilocin Clinical Supplies Are Ready For Upcoming Trials ↗

October 14, 2022

Canadian biotech company Lobe Sciences Ltd.

Via Benzinga

New Share Consolidation of Lobe Sciences Ltd., Here's What Changes ↗

June 08, 2022

Lobe Sciences Ltd.

Via Benzinga

Lobe Sciences Ltd (LOBEF) increases its portfolio with several new chemical entities (NCEs)

January 19, 2023

Via AB Newswire

Topics Intellectual Property

Trippy Trading: Top Psychedelic Stocks For 2023

January 17, 2023

When psychedelics were first studied more than 50 years ago, researchers discovered that they were useful in assisting people in exploring a greater sense of self. After a half-century hiatus,...

Via TheNewswire.com

Topics Cannabis

Lobe Sciences Announces Incorporation of Australian Subsidiary

September 23, 2022

Vancouver, British Columbia--(Newsfile Corp. - September 23, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"),...

Via Newsfile

Lobe Sciences Announces Closing of Private Placement

September 08, 2022

Vancouver, British Columbia--(Newsfile Corp. - September 8, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"),...

Via Newsfile

Psychedelics Funding At Its Best: $1.5 M Destined To Psilocybin Clinical Trials In Australia ↗

September 01, 2022

Psychedelics biopharma company Lobe Sciences Ltd.

Via Benzinga

Lobe Sciences and Cantheon Capital Enter into Exclusive Investment Agreement to Fund $1.5M USD Toward Clinical Trials in Australia

September 01, 2022

Vancouver, British Columbia--(Newsfile Corp. - September 1, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"),...

Via Newsfile

Topics Cannabis

This Psychedelic Company Just Signed An Exclusive Deal For Psilocin Clinical Trials In Australia ↗

August 10, 2022

Life sciences company Lobe Sciences Ltd.

Via Benzinga

Two Psychedelic Companies File Patent Applications For Psilocybin And MDMA Analogues, Here's What Could Change ↗

July 19, 2022

Mydecine (OTC: MYCOF) and Lobe Sciences (OTCQB: LOBEF), two companies in the psychedelics space, have filed patent applications.

Via Benzinga

Psyched: Elon Musk Tweets About Psychedelics, Numinus Acquires Novamind, Colorado Gov. Signs MDMA Legalization Bill ↗

June 15, 2022

Want to get the latest psychedelics industry news in your inbox every week? Subscribe to our Newsletter to become a Psychedelics Insider.

Via Benzinga

Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) Featured in Coverage of Planet MicroCap’s Virtual Investor Conference

April 19, 2022

Via Investor Brand Network

Lobe Sciences Ltd. (OTCQB: LOBEF) (CSE: LOBE) Featured in Coverage of Investor Summit Group’s Q1 Virtual Event

March 07, 2022

Via Investor Brand Network

< Previous 1 2 3 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.